Humana's 15min Chart Shows MACD Death Cross, Bollinger Bands Narrowing.

Humana's 15-minute chart has recently triggered a MACD Death Cross, as well as Bollinger Bands Narrowing, as of September 11, 2025 at 14:45. This suggests that the stock price has the potential to continue declining, with a notable decrease in the magnitude of price fluctuations.

Humana Inc. (HUM) recently experienced a MACD Death Cross and Bollinger Bands Narrowing on its 15-minute chart, as of September 11, 2025 at 14:45, according to technical analysis tools. These indicators suggest that the stock price may continue to decline, with a notable decrease in the magnitude of price fluctuations.

A MACD Death Cross occurs when the MACD line crosses below the signal line, indicating a potential bearish trend. Bollinger Bands Narrowing, on the other hand, suggests that the price volatility is decreasing, which can precede a significant price move in either direction. Given these indicators, investors should closely monitor Humana's stock performance.

In addition to the technical indicators, Humana's recent stock performance has been influenced by the managed care sector's sentiment. Bank of America (BofA) raised its price target on Humana to $330 from $312 on Tuesday, citing improved sentiment following UnitedHealth's preliminary Medicare Advantage Star Ratings update Humana Stock In Focus: BofA Raises Price Target After UnitedHealth Stars Data, Raymond James Sees Buying Opportunity^[1]. However, analysts at Raymond James cautioned that uncertainty over 2027 Medicare Advantage rates could delay Humana's earnings recovery.

The preliminary disclosure from UnitedHealth, covering Star Year 2026 and Payment Year 2027, is a key driver of future Medicare Advantage reimbursements. Wall Street analysts have expressed mixed sentiments, with some raising their targets while others maintaining their ratings Humana Stock In Focus: BofA Raises Price Target After UnitedHealth Stars Data, Raymond James Sees Buying Opportunity^[1].

As of September 10, 2025, Humana's stock has risen 8.6% year-to-date, while UnitedHealth's stock has declined 30.7% over the same period. Retail sentiment on Stocktwits was 'extremely bullish' for Humana, with 'extremely high' message volume, while it was 'bullish' for UnitedHealth with 'high' volume.

Investors should remain vigilant and consider the potential implications of these technical indicators and the broader market sentiment. Further analysis and monitoring of Humana's stock performance are recommended.

References:
Humana Stock In Focus: BofA Raises Price Target After UnitedHealth Stars Data, Raymond James Sees Buying Opportunity^[1] Bank of America (BofA) raised its price target on Humana to $330 from $312 on Tuesday, citing improved sentiment following UnitedHealth's preliminary Medicare Advantage Star Ratings update.